Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer

Cantargia AB ( (SE:CANTA) ) just unveiled an announcement.

Cantargia AB has announced that the first patient has been dosed in a Phase 1b/2 investigator-initiated trial at the Tisch Cancer Institute, Mount Sinai, testing its IL1RAP-targeting antibody nadunolimab in combination with an anti-PD-1 checkpoint inhibitor in up to 24 patients with chemotherapy-refractory, microsatellite stable metastatic colorectal cancer, a particularly hard-to-treat tumor type. The study, led by Dr. Dan Fang, aims not only to evaluate anticancer activity but also to generate extensive biomarker and translational data on IL-1 signaling and immune suppression in colorectal cancer, potentially broadening nadunolimab’s clinical footprint beyond pancreatic and lung cancers and reinforcing Cantargia’s position in immuno-oncology through collaboration with a leading U.S. cancer center.

The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK6.50 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.

More about Cantargia AB

Cantargia AB is a Swedish biotechnology company developing antibody-based therapies for life-threatening diseases, built around targeting the protein IL1RAP, which is implicated in various cancers and inflammatory conditions. Its lead oncology candidate, nadunolimab (CAN04), is in clinical development primarily in combination with chemotherapy for pancreatic cancer and non-small cell lung cancer, where it has shown signs of enhanced efficacy versus chemotherapy alone, while a second program, CAN10 for autoimmune and inflammatory diseases, was acquired by Otsuka Pharmaceutical in 2025. Cantargia is listed on Nasdaq Stockholm under the ticker CANTA.

Average Trading Volume: 4,551,719

Technical Sentiment Signal: Hold

Current Market Cap: SEK1.37B

Learn more about CANTA stock on TipRanks’ Stock Analysis page.